{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High-dose+influenza+virus+vaccine&page=7",
    "query": {
      "intervention": "High-dose influenza virus vaccine",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 156,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High-dose+influenza+virus+vaccine&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High-dose+influenza+virus+vaccine&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T21:06:08.693Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05501561",
      "title": "Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "Experimental: IIV-A Investigational IIV-A administered as a single dose intramuscularly on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Experimental: aIIV-B Investigational aIIV-B administered as a single dose intramuscularly on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Experimental: aIIV-C Investigational aIIV-C administered as a single dose intramuscularly on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Active Comparator: Licensed IIV IIV administered as a single dose intramuscularly on Day 1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1056,
      "start_date": "2022-08-25",
      "completion_date": "2023-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-10-13T21:06:08.693Z",
      "location_count": 47,
      "location_summary": "Tempe, Arizona • Huntington Beach, California • San Diego, California + 42 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Milford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05501561"
    },
    {
      "nct_id": "NCT06641180",
      "title": "Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "High-Dose trivalent influenza vaccine (Split virion, Inactivated)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard-dose trivalent influenza vaccine (Split virion, Inactivated)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "50 Years to 64 Years"
      },
      "enrollment_count": 1180,
      "start_date": "2024-11-04",
      "completion_date": "2025-06-24",
      "has_results": false,
      "last_update_posted_date": "2025-12-03",
      "last_synced_at": "2026-10-13T21:06:08.693Z",
      "location_count": 20,
      "location_summary": "Los Alamitos, California • Fort Myers, Florida • Hollywood, Florida + 16 more",
      "locations": [
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06641180"
    },
    {
      "nct_id": "NCT01666782",
      "title": "Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Influenza Viral Infections"
      ],
      "interventions": [
        {
          "name": "Standard Trivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High-Dose Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Saad Jamshed MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 105,
      "start_date": "2012-08",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2016-06-24",
      "last_synced_at": "2026-10-13T21:06:08.693Z",
      "location_count": 2,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01666782"
    },
    {
      "nct_id": "NCT06744205",
      "title": "A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TIV mRNA-neuraminidase (NA)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TIV mRNA-HA Vaccine 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Influenza Standard Dose Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Influenza Vaccine High Dose",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1162,
      "start_date": "2025-01-06",
      "completion_date": "2026-05-22",
      "has_results": false,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-10-13T21:06:08.693Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06744205"
    },
    {
      "nct_id": "NCT01436370",
      "title": "TIV and High Dose TIV in Subjects With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Trivalent inactivated influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 102,
      "start_date": "2011-10",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2014-12-24",
      "last_synced_at": "2026-10-13T21:06:08.693Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01436370"
    },
    {
      "nct_id": "NCT00532792",
      "title": "A/H5N1 Dose Ranging Study With Adjuvant Patch",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pandemic Influenza"
      ],
      "interventions": [
        {
          "name": "A/H5N1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Intercell USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 501,
      "start_date": "2007-08",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2012-03-14",
      "last_synced_at": "2026-10-13T21:06:08.693Z",
      "location_count": 5,
      "location_summary": "Vallejo, California • Miami, Florida • Kansas City, Kansas + 2 more",
      "locations": [
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00532792"
    },
    {
      "nct_id": "NCT01135329",
      "title": "Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "6 Months to 75 Years"
      },
      "enrollment_count": 15,
      "start_date": "2010-08",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-10-13T21:06:08.693Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01135329"
    },
    {
      "nct_id": "NCT07703514",
      "title": "Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "cH15/3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cH4/3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cH5/1N1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cH8/1N1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 60,
      "start_date": "2026-09-18",
      "completion_date": "2027-04-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-13T21:06:08.693Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07703514"
    },
    {
      "nct_id": "NCT01014806",
      "title": "Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Influenza VLP Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TIV",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 467,
      "start_date": "2009-11",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2013-07-18",
      "last_synced_at": "2026-10-13T21:06:08.693Z",
      "location_count": 6,
      "location_summary": "Pembroke Pines, Florida • Rochester, Minnesota • Providence, Rhode Island + 3 more",
      "locations": [
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01014806"
    },
    {
      "nct_id": "NCT03315104",
      "title": "Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza A H3N2",
        "Influenza A H1N1"
      ],
      "interventions": [
        {
          "name": "FLU-IGIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for FLU-IGIV",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2017-11-17",
      "completion_date": "2019-06-17",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-10-13T21:06:08.693Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03315104"
    }
  ]
}